Department of Medical Oncology, Hospital Universitario Central of Asturias, ISPA, Faculty of Medicine, University of Oviedo, Avenida de Roma S/N, Oviedo, Asturias, Spain.
Department of Medical Oncology, Hospital General Universitario Morales Meseguer, Murcia, Spain.
Clin Transl Oncol. 2023 Dec;25(12):3492-3500. doi: 10.1007/s12094-023-03214-5. Epub 2023 May 29.
This study investigated the impact of systemic cancer therapy on the quality of life, mental well-being, and life satisfaction of cancer patients.
This prospective study was promoted by the Spanish Society of Medical Oncology (SEOM) and enrolled patients with localized, resected, or unresectable advanced cancer from 15 Spanish medical oncology departments. Patients completed surveys on quality of life (EORTC-QoL-QLQ-C30), psychological distress (BSI-18) and life satisfaction (SWLS) before and after systemic cancer treatment.
The study involved 1807 patients, 944 (52%) having resected, localized cancer, and 863 with unresectable advanced cancer. The mean age was 60 years, and 53% were female. The most common types of localized cancer were colorectal (43%) and breast (38%), while bronchopulmonary (32%), non-colorectal digestive (23%), and colorectal (15%) were the most frequent among those with advanced cancer. Before systemic treatment, patients with advanced cancer had poorer scores than those with localized cancer on physical, role, emotional, cognitive, social limitations, symptoms, psychological distress, and life satisfaction (all p < 0.001), but there were no differences in financial hardship. Patients with localized cancer had greater life satisfaction and better mental well-being than those with advanced cancer before systemic treatment (p < 0.001). After treatment, patients with localized cancer experienced worsening of all scales, symptoms, and mental well-being (p < 0.001), while patients with advanced disease had a minor decline in quality of life. The impact on quality of life was greater on all dimensions except economic hardship and was independent of age, cancer location, and performance status in participants with resected disease after adjuvant chemotherapy.
In conclusion, our study highlights that systemic cancer treatment can improve quality of life in patients with advanced cancer, while adjuvant treatments for localized disease may have a negative impact on quality of life and psychological well-being. Therefore, treatment decisions should be carefully evaluated on an individual basis.
本研究旨在探讨全身性癌症治疗对癌症患者生活质量、心理健康和生活满意度的影响。
这项前瞻性研究由西班牙肿瘤内科学会(SEOM)发起,共纳入来自西班牙 15 个肿瘤内科科室的局限性、可切除或不可切除的晚期癌症患者。患者在接受全身性癌症治疗前后完成了生活质量(EORTC-QoL-QLQ-C30)、心理困扰(BSI-18)和生活满意度(SWLS)的问卷调查。
本研究共纳入 1807 例患者,其中 944 例(52%)为局限性、可切除癌症患者,863 例为不可切除的晚期癌症患者。患者的平均年龄为 60 岁,53%为女性。局限性癌症中最常见的类型为结直肠癌(43%)和乳腺癌(38%),而晚期癌症中最常见的类型为支气管肺癌(32%)、非结直肠消化系统癌症(23%)和结直肠癌(15%)。在接受全身性治疗前,晚期癌症患者在身体、角色、情感、认知、社会限制、症状、心理困扰和生活满意度等方面的评分均低于局限性癌症患者(均 p<0.001),但在经济困难方面无差异。在接受全身性治疗前,局限性癌症患者的生活满意度和心理健康状况均优于晚期癌症患者(p<0.001)。治疗后,局限性癌症患者的所有评分、症状和心理健康状况均恶化(p<0.001),而晚期疾病患者的生活质量略有下降。在接受辅助化疗的局限性疾病患者中,除经济困难外,生活质量的各个维度都受到了更大的影响,且与年龄、癌症部位和功能状态无关。
总之,本研究强调了全身性癌症治疗可以改善晚期癌症患者的生活质量,而局限性疾病的辅助治疗可能对生活质量和心理健康产生负面影响。因此,应根据个体情况仔细评估治疗决策。